Between January 2020 and August 2022, we retrospectively evaluated patients with advanced or metastatic EGFR mutation-positive NSCLC who underwent re-biopsy of suspected recurrent or progressive lesions after first- or second-generation EGFR-TKI treatment at the China Medical University Hospital, a tertiary referral center in Taiwan. We investigated the rate of detection of T790M at first-time re-biopsy using IP methods. We also performed repeat re-biopsy of T790M-negative tumors to evaluate the clinical value of repeat re-biopsy. Patients were excluded if re-biopsy was performed for the purpose of clinical trial enrollment without evidence of disease progression or if they had insufficient data for analysis. The study protocol was approved by the institutional ethics committee of the relevant institution (IRB number: CMUH110-REC1–244), and informed consent was waived due to the observational and retrospective study design. The study was conducted in accordance with the Declaration of Helsinki and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Data on baseline characteristics of each patient, including age, sex, smoking status, Eastern Cooperative Oncology Group Performance Status (ECOG PS), EGFR mutation subtype, tumor–node–metastasis (TNM) stage at initial diagnosis, first-line EGFR-TKI treatment, re-biopsy methods, re-biopsy sites, T790M status after re-biopsy, time interval between diagnosis and re-biopsy, and histology results, were reviewed in the electronic chart records.
2.2. Re-Biopsy Methods and EGFR T790M Mutation TestingPatients were diagnosed with advanced or metastatic EGFR-positive NSCLC at the initial biopsy, i.e., biopsy at the time of diagnosis. Re-biopsy was defined as a subsequently performed biopsy to screen for the acquired resistance mechanism (the T790M mutation) after the failure of any line of anti-cancer treatment. The first re-biopsy was defined as the biopsy performed for the first time after the failure of the first-line EGFR-TKI treatment, the second re-biopsy as the re-biopsy performed after the first re-biopsy, and so on. The biopsy procedures included IP methods (Figure 1)—bronchoscopy with radial probe-EBUS (R-EBUS), EBUS-TBNA, sono-guided biopsy, and medical pleuroscopy—as well as non-IP methods—CT-guided biopsy and surgery.The biopsy samples were divided into two groups: tissue sampled by the IP methods; and tissue sampled by the non-IP methods. The success rate of tissue acquisition was the number of patients with positive acquisition divided by the total number of patients who underwent re-biopsy. The samples were examined to determine whether they were malignant and whether enough tumor cells were collected for extraction and EGFR mutation testing. The EGFR T790M mutation status of tumor tissue samples was assessed using cobas® EGFR Mutation Test v2, a PCR-based commercial EGFR mutation detection kit.
2.3. Statistical AnalysisAll statistical analyses were performed using MedCalc for Windows version 18.10 (MedCalc Software, Ostend, Belgium). Data for normally distributed variables are expressed as the mean ± standard deviation, and data for non-normally distributed variables as the median and interquartile range. Continuous data with a normal distribution were analyzed using the t-test. Categorical variables are presented as the number and percentage and were analyzed using the chi-square test. A p-value of <0.05 was set as the critical value for statistical significance. Data were visualized with Microsoft Excel for iMac, version 16.30.
4. DiscussionSeveral previous studies have shown that the diagnostic yields of re-biopsy with VATS and CT-guided fine needle aspiration or core needle biopsy are excellent [22,23]. However, these methods are associated with a high risk of complications, including bleeding, pneumothorax, and morbidity. In contrast, complications are relatively few for IP methods. To the best of our knowledge, this is the first study to investigate the efficacy of all IP procedures as first-line methods for detecting the T790M mutation. We demonstrated that first-line use of IP methods are feasible and provide sufficient tissue for analysis of the acquired resistance mechanism. IP methods and non-IP methods were similar in their detection of the T790Mmutation. Repeat re-biopsy increased the rate of T790M positivity in NSCLC patients after EGFR-TKI failure.In the present study, all patients underwent first-time tissue re-biopsy with IP methods. Among the re-biopsy methods, bronchoscopy with R-EBUS and EBUS-TBNA were the two most used tools, yielding successful pathological diagnoses in 78–87.5% of the cases. The diagnostic rate was similar to that (73.4%) in a previous study [16]. Another study had an overall detection rate of 87% for re-biopsy of malignant cells by transbronchial biopsy (TBB) and EBUS-TBNA [15]. In Kim et al.’s study, the sensitivity, negative predictive value (NPV), and accuracy of EBUS-TBNA for re-biopsy were 95.6%, 82.7%, and 96.3%, respectively, and there were no major complications during the procedure [24]. Based on these results, bronchoscopy with R-EBUS and EBUS-TBNA have high diagnostic value with few complications.Previous studies reported an adequate specimen acquisition rate of 80–90% for CT-guided needle biopsy, but 14–20% of patients experienced biopsy-related complications [25,26]. The present study also found that CT-guided needle aspiration and surgery have higher diagnostic yields; however, the T790M mutation detection rate in all diagnostic samples was similar between bronchoscopy with R-EBUS or EBUS-TBNA and CT-guided needle biopsy or surgical resection (32.8–33.3% vs. 36.4–40.0%; p = 0.920). A meta-analysis reported that PTCNB can obtain an adequate sample rate of 86.9% for molecular analysis with a T790M mutation detection rate of 46.0% [27]. Goag et al. reported a 43.9% T790M mutation detection rate for bronchoscopy biopsy samples [16]. On the other hand, Kirita et al. obtained a higher rate of detection of the T790M mutation (56%) with TBB and EBUS-TBNA [15]. The inconsistency in the rates of detection of the T790M mutation between these studies may be explained by different testing methods, different biopsy sites, and tumor heterogeneity. However, these results suggest that bronchoscopy with R-EBUS and EBUS-TBNA are useful and provide sufficient tissue to identify resistance mutations.In the present study, the rate of detection of the T790M mutation in re-biopsy tissue by medical pleuroscopy was 46.2%. To the best of our knowledge, this is the first report of the use of medical pleuroscopy to detect the T790M mutation. Masatsugu et al. suggested that thoracoscopic biopsy can help to detect the T790M mutation with low morbidity [19]. Tissue sampling by thoracoscopy under local anesthesia can reveal the T790M mutation [20]. Thoracentesis with cytology evaluation of malignant pleural fluid is commonly performed to detect the T790M mutation, with a detection rate of 44.4–54.7% [28,29,30]. However, acquired resistance to EGFR-TKIs varies. In addition to the T790M mutation of the target gene, other genomic mutations, alternative pathway activation, or histological transformation should be considered [31]. In the present study, histological transformation was diagnosed in 7.5% of re-biopsy samples. In a large retrospective cohort study, histological transformation occurred in approximately 3% of EGFR-mutated patients who progressed to EGFR-TKI therapy [32]. Therefore, medical pleuroscopy may be advantageous for additional analysis of the resistance mechanism and evaluation of histological transformation if the tissue sample volume is sufficient.The clinical value of repeat re-biopsy after the first re-biopsy of T790M-negative patients has been previously discussed. The CS-Lung-003 study reported that repeat re-biopsy increased the T790M positivity rate from 43% to 57% [30]. A real-world study also indicated that repeat re-biopsy could increase the detection rate of T790M-positive NSCLC patients from 53.1% to 71% [33]. Repeat re-biopsy may increase the T790M positivity rate even up to 80% [34]. Lee et al. found that the highest success rate of repeat biopsy was 78% and the rate of detection of the T790M mutation in multiple or delayed repeat biopsy samples was 40% [35]. The present study also shows that repeat re-biopsy can increase the number of patients detected with the T790M mutation after second-line treatment. This implies that multiple repeat re-biopsies are needed in some cases because of tumor heterogeneity.Kim et al. found a higher T790M mutation detection rate with re-biopsy of metastatic lesions than with biopsy of the primary tumor [26]. Another previous study also observed a higher T790M mutation detection rate in metastatic mediastinum lymph nodes than in the primary tumor [16]. Consistent with previous reports, the present study found a higher T790M mutation detection rate, although not statically significant, in re-biopsies of metastatic sites, including the liver, pleural tissue, and bone. The rate of detection of the T790M mutation in different locations varies due to considerable tumor heterogeneity. Therefore, compared to CT-guided biopsy and VAST, the IP procedures in the present study—bronchoscopy with R-EBUS or EBUS-TBNA, ultrasound-guided PNB, and medical pleuroscopy—are more convenient and comprehensive methods that provide the interventional pulmonologist with the means to overcome the obstacle of tumor heterogeneity.The present study has some limitations. First, it employed a retrospective study design with a limited number of patients and focused on re-biopsy tissue obtained by IP methods. Second, there was an imbalance in the number of tissue samples acquired with IP methods and those obtained with non-IP methods; this might have affected the study’s findings that support and confirm the greater usefulness of IP methods than of non-IP methods as first-line approaches. Third, the data were mostly based on histologic evaluation and single-gene EGFR testing using the the cobas® EGFR Mutation Test v2; they were not based on the next-generation sequencing (NGS) and liquid biopsy were not widely used in clinical practice due to its high price. These tests are not covered by health insurance. As a result, we could not identify other mutations and concurrent generic alternation. Finally, we did not assess the prognosis of patients with or without the T790M mutation, which was considered in a previous study [10]. The essential point of our study was to evaluate the feasibility and utility of IP procedures as first-line methods for detecting the T790M mutation, which could increase the number of patients accessing subsequent osimertinib therapy.
Comments (0)